Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Vanguard Dividend Appreciation Index Fund ETF trades at $246.54. Which is the better fit depends on your goals.
| ACAD | VIG | |
|---|---|---|
Market Cap | $5.06B | — |
Sector | Health | — |
52-Week High | $29.41 | $245.79 |
52-Week Low | $20.06 | $208.67 |
Enterprise Value | $4.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
VIG trades at $245.23, up 0.35% over 24 hours, with a bullish technical signal driven by moving averages and a dividend of $1.00 scheduled for June 2026. The ETF focuses on dividend growth, holding stocks like Broadcom, which has surged 710% over five years (24/7 Wall Street, 2026-07-22).
The outlook is positive for long-term investors seeking steady income, supported by a 20-year dividend growth streak, but risks include high RSI levels indicating overbought conditions and potential market volatility from AI and interest rate uncertainties (Zacks Investment Research, 2026-07-30).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
